www.AstraZeneca.co.za

Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ et al. An evidence-based appraisal of reflux disease management – the Genval Workshop Report. Gut 1999;44 Suppl 2:S1–16.
Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Survey. J Clin Outcomes Man 2000;7:29–34.
Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R and the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900–20.
Jasani K, Piterman L, McCall L. Gastroesophageal reflux and quality of life. Patient’s knowledge, attitudes and perceptions. Aust Fam Physician 1999;28 Suppl 1:S15–18.
Wahlqvist P, Carlsson J, Ståhljammar N-O, Wiklund I. Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-oesophageal reflux disease (WPAI-GERD) – results from a cross-sectional study. Value Health 2002;5:106–13.
Malfertheiner P, Hallerbäck B. Clinical manifestations and complications of gastroesophageal reflux. Int J Clin Pract 2005;59:346–55.
Miner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a 5-way cross-over study. Am J Gastroenterol 2003;98:2616–20.
Miner P, Katz P, Chen Y, Sostek M. Reanalysis of intragastric pH results based on updated correction factors for Slimline and Zinetics 24 single-use pH catheters. Am J Gastroenterol 2006;101:404–5, 406.
Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004;24:1–7.
Kahrilas P, Falk G, Johnson D, Schmitt C, Collins D, Whipple J et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249–58.
Richter J, Kahrilas J, Johanson J, Maton P, Breiter J, Hwang C et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656–65.
Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:926–35.
Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27–34.
Lauritsen K, Junghard O, Eklund S, Wiklund I. The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux esophagitis. Gastroenterology 2002;122:A200 (and associated poster).
Talley N Junghard O, Wiklund I. Improvement in health-related quality of life following esomeprazole treatment in patients with endoscopy-negative gastroesophageal reflux disease. J Gastroenterol Hepatol 2002;17 Suppl:A18.